NYSE:NVO - Novo Nordisk A/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$48.12 +0.47 (+0.99 %)
(As of 01/18/2019 03:32 PM ET)
Previous Close$47.65
Today's Range$47.80 - $48.49
52-Week Range$41.23 - $58.37
Volume131,942 shs
Average Volume1.34 million shs
Market Capitalization$114.53 billion
P/E Ratio20.58
Dividend Yield1.40%
Beta0.66
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk A/S has a research and licensing agreement with DUKE National University Singapore Medical School to develop stem cell-based treatments for chronic heart failure and age-related macular degeneration; and a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S has a collaboration agreement with Embark Biotech ApS for the discovery of novel treatments for obesity and its associated metabolic pathologies. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone45-4444-8888

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.96 billion
Cash Flow$2.6353 per share
Book Value$3.10 per share

Profitability

Net Income$5.79 billion

Miscellaneous

Employees42,076
Outstanding Shares2,443,530,000
Market Cap$114.53 billion
OptionableOptionable

Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S announced a special dividend on Thursday, August 9th. Stockholders of record on Monday, August 20th will be given a dividend of $0.4669 per share on Tuesday, August 28th. This represents a dividend yield of 1.72%. The ex-dividend date is Friday, August 17th. View Novo Nordisk A/S's Dividend History.

How will Novo Nordisk A/S's stock buyback program work?

Novo Nordisk A/S announced that its Board of Directors has initiated a stock buyback program on Friday, February 2nd 2018, which allows the company to repurchase outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's board of directors believes its shares are undervalued.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) announced its earnings results on Thursday, November, 1st. The company reported $0.58 EPS for the quarter, hitting the Zacks' consensus estimate of $0.58. The company earned $4.31 billion during the quarter, compared to the consensus estimate of $4.11 billion. Novo Nordisk A/S had a net margin of 34.94% and a return on equity of 81.50%. View Novo Nordisk A/S's Earnings History.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Thursday, February 7th 2019. View Earnings Estimates for Novo Nordisk A/S.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S updated its FY 2018 earnings guidance on Thursday, November, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $17.425-17.592 billion, compared to the consensus revenue estimate of $17.33 billion.

What is the consensus analysts' recommendation for Novo Nordisk A/S?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.

Has Novo Nordisk A/S been receiving favorable news coverage?

Media coverage about NVO stock has been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novo Nordisk A/S earned a news impact score of 0.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the immediate future.

Who are some of Novo Nordisk A/S's key competitors?

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the folowing people:
  • Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 52)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 58)
  • Mr. Jesper Brandgaard, Exec. VP and Head of Biopharm & Legal Affairs (Age 55)
  • Ms. Liselotte Hyveled, Former Project VP for Faster-Acting Insulin Aspart & Prandial Bioedge Projects - Insulin & Director (Age 52)
  • Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 46)

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Saratoga Research & Investment Management (0.06%), Alta Capital Management LLC (0.04%), Scout Investments Inc. (0.01%), Ferguson Wellman Capital Management Inc. (0.01%), JLB & Associates Inc. (0.01%) and Smithbridge Asset Management Inc. DE (0.00%). View Institutional Ownership Trends for Novo Nordisk A/S.

Which major investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Saratoga Research & Investment Management, Alta Capital Management LLC, JLB & Associates Inc., Gradient Investments LLC, Kavar Capital Partners LLC, Pennsylvania Trust Co and Bath Savings Trust Co. View Insider Buying and Selling for Novo Nordisk A/S.

Which major investors are buying Novo Nordisk A/S stock?

NVO stock was purchased by a variety of institutional investors in the last quarter, including Capital Insight Partners LLC, Douglas Lane & Associates LLC, Quadrant Capital Group LLC, Ferguson Wellman Capital Management Inc., Personal Capital Advisors Corp, Ipswich Investment Management Co. Inc., Moody National Bank Trust Division and Smithbridge Asset Management Inc. DE. View Insider Buying and Selling for Novo Nordisk A/S.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $48.12.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $114.53 billion and generates $16.96 billion in revenue each year. The company earns $5.79 billion in net income (profit) each year or $2.34 on an earnings per share basis. Novo Nordisk A/S employs 42,076 workers across the globe.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is http://www.novonordisk.com.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]


MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  276 (Vote Outperform)
Underperform Votes:  363 (Vote Underperform)
Total Votes:  639
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2019 by MarketBeat.com Staff

Featured Article: Roth IRA

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel